A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China
Related Experiment Video
Updated: May 31, 2026
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
1Department of Hematology, Affiliated Shengjing Hospital of China Medical University, Shenyang, China.
Objective:
To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China.
Methods:
We conducted this study in the Affiliated Shengjing Hospital of China Medical University, Shenyang, China between June and December 2010. We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials (RCTs) of Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma by computer databases during the period 2004-2009.
Results:
Seven trials involving 357 patients were retrieved. The complete remission rate of Rituximab combined CHOP chemotherapy was higher than that of CHOP chemotherapy alone (odds ratio = 3.02, 95% confidence interval: 1.94-4.72, p<0.00001).
Conclusion:
Non-Hodgkin lymphoma treated by Rituximab combined CHOP chemotherapy can produce a positive therapeutic effect in China.